Floatz logo

Azacitidine

Monomorphic Epitheliotropic Intestinal T-Cell Lymphoma

National Cancer Institute (NCI)Small moleculePhase 2Active
B
60/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
45/ 100
Competitive Position
95/ 100

Competitive context

19 Active assets in the Monomorphic Epitheliotropic Intestinal T-Cell Lymphoma cohort.

Asset / SponsorPhaseRating
Cyclophosphamide
National Cancer Institute (NCI)
Phase 2BB
Inno-206
Eric Jacobsen, MD
Phase 2B
Azacitidine
National Cancer Institute (NCI)
Phase 2B
Duvelisib
National Cancer Institute (NCI)
Phase 2CCC
Cerdulatinib
Portola Pharmaceuticals
Phase 2/3CCC

View all 20 →

Same molecule, other indications

Azacitidine is also rated in:

acute myeloid leukemia with abnormal bone marrow eosinophils inv(16)(p13q22) or t(16;16)(p13;q22)Dormant
BBB
Indicative ·
73 / 100
View asset →
acute erythroid leukemiaDormant
BB
Indicative ·
71 / 100
View asset →
non-small cell lung carcinomaDormant
BB
Indicative ·
71 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →